PLAU and neoplasm: To explore the anti-tumor effect of ProIFN, we first determined the expression levels of tumor-enriched enzymes such as MMP-2, MMP-9, MMP-11, MMP-14, fibroblast activation protein alpha (FAP), and urokinase plasminogen activator (uPA) in a variety of tumor lines.